69 related articles for article (PubMed ID: 10902272)
1. [Soluble Fas in acute rejection in patients with liver transplantation. Response to treatment].
Rivero M; Crespo J; Mayorga M; Fábrega E; de las Heras B; Almohalla C; Pons-Romero F
Gastroenterol Hepatol; 2000 May; 23(5):215-8. PubMed ID: 10902272
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the Fas system in liver allograft rejection.
Rivero M; Crespo J; Mayorga M; Fábrega E; Casafont F; Pons-Romero F
Am J Gastroenterol; 2002 Jun; 97(6):1501-6. PubMed ID: 12094873
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
Jun EJ; Han JY; Sun HS
Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
[TBL] [Abstract][Full Text] [Related]
4. Evolution of soluble forms of CD86, CD95 and CD95L molecules in liver transplant recipients.
Marín LA; Moya-Quiles MR; Miras M; Minguela A; Bermejo J; Ramírez P; García-Alonso AM; Parrilla P; Alvarez-López MR; Muro M
Transpl Immunol; 2012 Mar; 26(2-3):94-100. PubMed ID: 22182632
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
6. [Serum level and urinary excretion of soluble Fas (sFas) in patients with primary glomerulopathies].
Kacprzyk F
Pol Arch Med Wewn; 2002 Sep; 108(3):843-7. PubMed ID: 12600180
[TBL] [Abstract][Full Text] [Related]
7. Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose.
Tagami A; Ohnishi H; Hughes RD
Hepatogastroenterology; 2003; 50(51):742-5. PubMed ID: 12828076
[TBL] [Abstract][Full Text] [Related]
8. Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation.
Bewick M; Conlon M; Parissenti AM; Lee H; Zhang L; Glück S; Lafrenie RM
J Hematother Stem Cell Res; 2001 Dec; 10(6):759-68. PubMed ID: 11798502
[TBL] [Abstract][Full Text] [Related]
9. Circulating soluble Fas concentration in breast cancer patients.
Ueno T; Toi M; Tominaga T
Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease.
Chen DY; Lan JL; Lin FJ; Hsieh TY
Clin Rheumatol; 2007 Mar; 26(3):393-400. PubMed ID: 16972019
[TBL] [Abstract][Full Text] [Related]
12. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?
Bijl M; van Lopik T; Limburg PC; Spronk PE; Jaegers SM; Aarden LA; Smeenk RJ; Kallenberg GG
J Autoimmun; 1998 Oct; 11(5):457-63. PubMed ID: 9802929
[TBL] [Abstract][Full Text] [Related]
13. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus.
Al-Maini MH; Mountz JD; Al-Mohri HA; El-Ageb EM; Al-Riyami BM; Svenson KL; Zhou T; Richens ER
Lupus; 2000; 9(2):132-9. PubMed ID: 10787011
[TBL] [Abstract][Full Text] [Related]
16. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
Nakae H; Narita K; Endo S
J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the fas system in hepatitis C virus recurrence after liver transplantation.
Crespo J; Rivero M; Mayorga M; Fabrega E; Casafont F; Gomez-Fleitas M; Pons-Romero F
Liver Transpl; 2000 Sep; 6(5):562-9. PubMed ID: 10980054
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of the sFas/sFasL system in psoriatic patients.
Myśliwiec H; Baran A; Myśliwiec P; Górska M; Flisiak I
Adv Med Sci; 2015 Mar; 60(1):64-8. PubMed ID: 25437350
[TBL] [Abstract][Full Text] [Related]
19. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
[TBL] [Abstract][Full Text] [Related]
20. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.
Song le H; Binh VQ; Duy DN; Bock TC; Kremsner PG; Luty AJ; Mavoungou E
J Med Virol; 2004 Jun; 73(2):244-9. PubMed ID: 15122799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
